GSK to Acquire Nuvalent for $10.6 Billion in All-Cash Tender Offer
NUVL sits 73% above its 52-week low of $71.13 on elevated volume (35× avg).
Summary
Nuvalent, Inc. will be acquired by GlaxoSmithKline LLC for $10.6 billion in an all-cash tender offer, offering shareholders $124 per share and integrating Nuvalent's advanced oncology pipeline into GSK.
Key Events · M&A and Partnerships · NUVL
-
Acquisition Agreement Announced
GlaxoSmithKline LLC (GSK) will acquire Nuvalent, Inc. for $10.6 billion in an all-cash tender offer, with shareholders receiving $124 per share.
-
Significant Shareholder Premium
The offer price of $124 per share represents a 40% premium to Nuvalent's last closing price and a 26% premium to its 30-day volume-weighted average price (VWAP).
-
Strategic Oncology Pipeline Expansion
GSK gains two late-stage precision oncology candidates, neladalkib (for ALK+ NSCLC) and zidesamtinib (for ROS1+ NSCLC), both with FDA Breakthrough Therapy & Orphan Drug Designations and expected approvals in 2026.
-
Transaction Expected to Close in Q3 2026
The acquisition is anticipated to be completed in the third quarter of 2026, pending regulatory approvals.
Analysis · NUVL · Life Sciences
This SC TO-C filing formally announces the planned cash tender offer by GlaxoSmithKline LLC (GSK) to acquire Nuvalent, Inc. for an aggregate consideration of $10.6 billion, or $124 per share. This represents a substantial premium for Nuvalent shareholders and marks a definitive, company-transforming event. The acquisition provides GSK with two late-stage precision oncology assets, neladalkib and zidesamtinib, both under FDA review with potential approvals in 2026, significantly enhancing GSK's lung cancer pipeline.
At the time of this filing, NUVL was trading at $123.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $71.13 to $123.62. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.